ROARABLE // PRO
GLOBAL DESKS // NYC --:--:-- NYSE
US TAPE
ROAR ▸
COMP <GO>

DYAI vs ABOS // RETURN ON INVESTED CAPITAL (ROIC)

Dyadic International Inc. (NASDAQ) VS. Acumen Pharmaceuticals Inc. (NASDAQ) • 15-METRIC TALLY: DYAI 2 — ABOS 0
■ METRIC PARITY
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (DYAI VS. ABOS) EMERALD CELL = QUANTITATIVE EDGE
INSTITUTIONAL METRIC DYAI ABOS SPREAD (A - B) ADVANTAGE DEDICATED URL
Gross Profit Margin 24.90% — — TIE /gross-margins <GO>
Return on Invested Capital (ROIC) ACTIVE -35.00% -35.00% 0.00 TIE /roic <GO>
EV/EBITDA & P/E Valuation — — — TIE /valuation <GO>
Free Cash Flow Yield — — — TIE /fcf-yield <GO>
Operating Margin -60.00% — — TIE /operating-margins <GO>
Net Profit Margin -60.00% — — TIE /net-margins <GO>
Revenue Growth (YoY) -11.60% — — TIE /revenue-growth <GO>
Dividend Yield & FCF Payout Safety 0.00% 0.00% 0.00 TIE /dividend-safety <GO>
Altman Z-Score & Debt/Equity — — — TIE /balance-sheet <GO>
Piotroski F-Score Quality 2/9 2/9 0.00 TIE /piotroski-score <GO>
Options Implied Move & Put/Call Skew — — — TIE /options-implied-move <GO>
RSI-14 & 200D SMA Momentum 40.8 20.3 +20.50 DYAI /rsi-technicals <GO>
10Y Yield & FRED Macro Beta — — — TIE /macro-sensitivity <GO>
Forward P/E Multiple — — — TIE /forward-pe <GO>
Enterprise Scale & Market Cap $15.2M $15.2M $36.3K DYAI /market-cap <GO>
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
FISCAL YEAR DYAI REV ABOS REV DYAI GROSS % ABOS GROSS % DYAI FCF ABOS FCF
FY 2025 $3.1M $346.7M 24.9% — -$5.7M -$115.5M
FY 2024 $3.5M $319.2M 65.8% — -$4.0M -$86.2M
FY 2023 $2.9M $171.2M — — -$6.7M -$43.1M
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
DYAI // BETA —
ABOS // BETA —